Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Salary Range:CHF93,800.00 - CHF174,200.00 BandLevel 4 Job Description Summary#LI-Hybrid Location: Basel, Switzerland or Cambridge, United States (see separate posting) Relocation Support: This role is based in Basel, Switzerland. Novartis is unable to offer relocation support: please only apply
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)